Generic Medicine Info
Viral diseases of the cornea and conjunctiva (e.g. epithelial herpes simplex keratitis [dendritic keratitis], vaccinia, varicella); mycobacterial eye infection, fungal disease of ocular structures, acute purulent untreated bacterial eye infections.
Special Precautions
Patient with glaucoma; history of herpes simplex, undiagnosed red eye, disease causing thinning of corneal or scleral tissue. Use after cataract surgery. Avoid abrupt withdrawal (particularly in chronic conditions). Children. Pregnancy and lactation. Patient Counselling This drug may cause transient blurred vision; if affected, do not drive or operate machinery. Remove contact lenses before administration and wait at least 15 minutes prior to reinsertion. Monitoring Parameters Monitor intraocular pressure regularly particularly when used for ≥10 days and in patients with glaucoma; signs and symptoms of secondary infection. Perform frequent slit lamp microscopy particularly in patients with history of herpes simplex.
Adverse Reactions
Significant: Posterior subcapsular cataract formation, corneal and scleral thinning leading to perforation, optic nerve damage, defects in visual acuity and fields of vision, delayed corneal wound healing, secondary ocular infection (e.g. fungal infection), increased intraocular pressure and/or glaucoma (prolonged use); increased incidence of bleb formation (after cataract surgery), blurred vision. Rarely, central serous chorioretinopathy. Eye disorders: Eye pain, irritation, pruritus, and swelling; transient burning and stinging sensation of eyes, ocular hyperaemia, eyelid oedema, mydriasis, increased lacrimation, foreign body sensation in the eyes, eye discharge. Gastrointestinal disorders: Dysgeusia. Immune system disorders: Hypersensitivity reaction. Skin and subcutaneous tissue disorders: Rash.
Drug Interactions
May delay the healing of ophthalmic tissue when used with ophthalmic NSAIDs. May increase the risk of systemic adverse effects with CYP3A4 inhibitors (e.g. cobicistat-containing agents, ritonavir).
CIMS Class
Eye Corticosteroids
ATC Classification
S01BA07 - fluorometholone ; Belongs to the class of corticosteroids. Used in the treatment of inflammation of the eye.
D10AA01 - fluorometholone ; Belongs to the class of topical corticosteroids used in the treatment of acne.
D07XB04 - fluorometholone ; Belongs to the class of moderately potent (group II) corticosteroids in other combinations. Used in the treatment of dermatological diseases.
S01CB05 - fluorometholone ; Belongs to the class of corticosteroids/antiinfectives/mydriatics combinations. Used in the treatment of eye diseases.
D07AB06 - fluorometholone ; Belongs to the class of moderately potent (group II) corticosteroids. Used in the treatment of dermatological diseases.
C05AA06 - fluorometholone ; Belongs to the class of products containing corticosteroids for topical use. Used in the treatment of hemorrhoids and anal fissures.
Disclaimer: This information is independently developed by CIMS based on fluorometholone from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to CIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, CIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2021 CIMS. All rights reserved. Powered by CIMSAsia.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in